Brought to you by the Roche diagnostics family, because we believe in the power of knowing more about cancer diagnostics.

Footnotes and references


*As of 2011

1. Personalized Medicine Is Playing a Growing Role in Development Pipelines: Tufts Center for the Study of Drug Development. Impact Report, 12 (November/December 2010): 6

2. Personalised Healthcare Perception Study – Laboratory heads, Summary of key findings 8 April 2014, Ebiquity Research, UK

3. KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies D. Soulières, W. Greer, Anthony M. Magliocco, D. Huntsman, S. Young, M.-S. Tsao, S. Kamel-Reid Curr Oncol. 2010 July; 17 (Suppl 1): S31–S40.

4. Clinical success rates for new cancer drugs double while more enter testing. Tufts Center for the Study of Drug Development. Impact Report, 15 (May/June 2013) 3


© 2014 Ventana Medical Systems, Inc.

VENTANA and the VENTANA logo are trademarks of Roche. All other trademarks are the property of their respective owners. WEB5258 0514A

Scroll down to view

Potential for longer life

Potential for improved quality of life

Potential for fewer side affects

Identify patients for personalized therapies 
with companion diagnostics


Clinical confidence in regulated, validated biomarkers that link to personalized therapies


Consult with oncologist as a member of the patient’s treatment team


Companion diagnostics bring high value to labs


Lab professionals report job satisfaction in doing
tests that make a real difference to patients


New technologies bring broader testing capabilities

Potential for a healthier, more productive community


Lower cost healthcare overall4


Reduced spending on ineffective treatments4


Reduced cost of clinical trials—close to 2/3 of cost
in some cases4

Better options for more patients


Improved targeted care pathways4


Increased quality of clinical practice4